IP Library Granted Patent US 7,083,787
Granted Patent B2
US 7,083,787 · App. 09/991,363 · Granted Aug 1, 2006

Yeast-dendritic cell vaccines and uses thereof

Assignees: GlobeImmune, Inc.; The Regents of the University of Colorado
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,083,787
App. No.
09/991,363
Granted
Aug 1, 2006
Kind
B2
Abstract

Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.

Claims (23)

1. An immunogenic composition, comprising:

a) an isolated dendritic cell;

b) a yeast vehicle selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast particle; and,

c) at least one immunogen that is heterologous to the yeast vehicle and that is not expressed by or loaded into the yeast vehicle;

wherein said dendritic cell has been loaded intracellularly with said yeast vehicle and said at least one immunogen.

2. The immunogenic composition of claim 1 , wherein said immunogen is selected from the group consisting of viral antigens, mammalian cell surface molecules, bacterial antigens, fungal antigens, protozoan antigens, helminth antigens, ectoparasite antigens, and cancer antigens.

3. The immunogenic composition of claim 1 , wherein said immunogen is selected from the group consisting of: HIV-1 gag, HIV-1 env, HIV-1 pol, HIV-1 tat, HIV-1 nef, HbsAG, HbcAg, hepatitis c core antigen, HPV E6 and E7, HSV glycoprotein D, and Bacillus anthracis protective antigen.

4. The immunogenic composition of claim 1 , wherein said composition comprises multiple immunogens.

5. The immunogenic composition of claim 1 , wherein said composition further comprises at least one biological response modifier.

6. The immunogenic composition of claim 1 , wherein said yeast vehicle is selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, and a yeast ghost.

7. The immunogenic composition of claim 1 , wherein said yeast vehicle is selected from the group consisting of: a whole yeast and a yeast spheroplast.

8. The immunogenic composition of claim 1 , wherein said yeast vehicle is a whole yeast.

9. The immunogenic composition of claim 1 , wherein said yeast is a nonpathogenic yeast.

10. The immunogenic composition of claim 1 , wherein said yeast is of a genus selected from the group consisting of Saccharomyces, Candida, Cryptococcus, Hansenula, Kluyveromyces, Pichia, Rhodotorula, Schizosaccharomyces and Yarrowia.

11. A method to produce an immunogenic composition, comprising loading a dendritic cell intracellularly with:

a) a yeast vehicle selected from the group consisting of: a whole yeast, a yeast spheroplast, a yeast cytoplast, a yeast ghost, and a subcellular yeast particle; and,

b) at least one immunogen that is heterologous to said yeast vehicle and that is not expressed by or loaded into the yeast vehicle.

12. The method of claim 11 , wherein said step of loading a dendritic cell is accomplished by a method selected from the group consisting of: diffusion, active transport, liposome fusion, electroporation, phagocytosis, and bath sonication.

13. An immunogenic composition produced by the method of claim 11 .

14. A method to elicit an antigen-specific humoral immune response and an antigen-specific cell-mediated immune response in a mammal, said method comprising administering to said mammal the immunogenic composition of claim 1 .

15. The method of claim 14 , wherein said immunogenic composition is administered by a route selected from the group consisting of: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal, intramuscular, transdermal, inhaled, intranasal, oral, intraocular, intraarticular, intracranial, and intraspinal.

16. The method of claim 14 , wherein said immunogenic composition is administered with a pharmaceutically acceptable excipient.

17. A method to elicit an antigen-specific humoral immune response and an antigen-specific cell-mediated immune response in a mammal, said method comprising administering to said mammal the immunogenic composition of claim 13 .

Assignments (6)
CONFIRMATORY LICENSE Recorded Nov 14, 2018
From: THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
To: NIH - DIETR
Reel/Frame 047496/0502 →
CONFIRMATORY LICENSE Recorded May 14, 2008
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020945/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2004
From: UNIVERSITY TECHNOLOGY CORPORATION
To: REGENTS OF THE UNIVERSITY OF COLORADO, THE
Reel/Frame 015517/0607 →
MERGER Recorded Apr 21, 2003
From: CERES PHARMACEUTICALS, LTD.
To: GLOBEIMMUNE, INC.
Reel/Frame 013972/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2002
From: WILSON, CARA C.
To: UNIVERSITY TECHNOLOGY CORPORATION
Reel/Frame 012628/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2002
From: DUKE, RICHARD C.; BELLGRAU, DONALD; FRANZUSOFF, ALEX
To: CERES PHARMACEUTICALS, LTD. D/B/A GLOBEIMMUNE, INC.
Reel/Frame 012628/0433 →
Continuity (2)
Provisional Application 6024917300 · Nov 15, 2000
Related Publication 20060104986A1 · May 18, 2006